Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
daratumumab (Darzalex®)
Reference No. 2834
Publication date:
30/09/2016
Appraisal information
daratumumab (Darzalex®) 20 mg/ml concentrate for solution for infusion
Company:
Janssen-Cilag Ltd
BNF category:
Malignant disease and immunosupression
NMG meeting date:
Not scheduled
AWMSG meeting date:
Not scheduled
Submission Type:
Nonsubmission
Status:
Superseded
Advice No:
Not available
Ratification by Welsh Government:
29/09/2016
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA510) ISSUED JANUARY 2018 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)
Statement of Advice (SOA)
Download
daratumumab (Darzalex) 2834 SOA